Table 2 Successful use of letrozole in the treatment of endometriosis associated symptoms
From: The emerging use of aromatase inhibitors for endometriosis treatment
Patient group | Summary of Results | Reference |
|---|---|---|
Pre-menopausal women (N = 1) (endometriosis resistant to conventional therapy) | Decreased pelvic pain, affect on implant mass not determined | [23] Verme & Konje |
Pre-menopausal women (N = 10) (endometriosis resistant to conventional therapy) | Decrease in pelvic pain Decrease in implant mass | [24] Ailawadi et al. |
Pre-menopausal women (N = 82) (intolerant/failed previous treatment, severe pain symptoms, N = 37 Letrozole + norethisterone acetate vs. N = 38 Norethisterone acetate alone) | Decrease in pelvic pain and deep dyspareunia, affect on implant mass unknown | [25] Ferrero et al. |
Pre-menopausal women (N = 2) (bladder endometriosis, non-responsive to conventional therapy, pelvic pain and urinary symptoms) | Decreased pelvic pain and urinary symptoms, affect on implant mass not determined | [26] Ferrero et al. |
Women with colorectal endometriosis (N = 6; pain and intestinal symptoms) | Decreased pain and intestinal symptoms, affect on implant mass unknown | [27] Ferrero et al. |
Pre-menopausal women (N = 5) (recurrent ovarian endometriosis, chronic pelvic pain) | Decreased pelvic pain, decreased implant mass | [28] Lall et al. |
Pre-menopausal women (N = 1) (recurrent endometriosis resistant to conventional therapy, pelvic pain dyspareunia) | Decreased pelvic pain and dyspareunia, affect on implant mass not determined | [29] Razzi et al. |
Post-menopausal woman (N = 1) (recurrent endometrioma, pain) | Decreased pain, decrease in implant mass | [30] Fatemi et al. |
Post-menopausal woman (N = 1) (severe pelvic pain) | Decreased pelvic pain, affect on implant mass unknown | [31] Mousa et al. |
Post-menopausal woman (N = 1) (recurrent abdominal wall endometriosis) | Decreased implant mass | [32] Sasson & Taylor |